Related references
Note: Only part of the references are listed.Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
Michael. S. van der Veer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Delivery of NKG2D Ligand Using an Anti-HER2 Antibody-NKG2D Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response
Hyun-Mi Cho et al.
CANCER RESEARCH (2010)
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC
Atsushi Inagaki et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Up on the tightrope: natural killer cell activation and inhibition
Lewis L. Lanier
NATURE IMMUNOLOGY (2008)
NKG2D ligands in tumor immunity
N. Nausch et al.
ONCOGENE (2008)
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
EP von Strandmann et al.
BLOOD (2006)
NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway
DD Billadeau et al.
NATURE IMMUNOLOGY (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
